Welcome to our dedicated page for Dss SEC filings (Ticker: DSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a company that patents anti-counterfeit labels and finances commercial loans can feel like reading five annual reports at once. DSS Inc’s filings weave together packaging security, biotech trials, lending portfolios, and investment gains—details investors can’t afford to miss but rarely have time to untangle.
Stock Titan solves that problem. Our AI reads every DSS Inc quarterly earnings report 10-Q filing, scans each DSS Inc insider trading Form 4 transaction, and highlights what moves markets. Instead of parsing footnotes, you’ll see plain-English callouts—IP valuation swings, biotech milestone expenses, or credit-loss reserves—delivered the moment EDGAR releases them. Looking for the next Form 4 insider transactions real-time alert? Want the DSS Inc annual report 10-K simplified to a five-minute brief? It’s already waiting on this page.
Use the navigation below to answer questions professionals ask every quarter: How did packaging security margins shift? Which executives bought shares after a new patent license? Our coverage spans:
- 8-K material events explained—patent wins, biotech data, or loan impairments
- Proxy statement executive compensation insights for DSS Inc’s diverse leadership
- Earnings report filing analysis comparing segment revenues over time
Whether you’re understanding DSS Inc SEC documents with AI for the first time or need a quick refresh before a call, this hub keeps you current, confident, and ahead of the curve.
DSS, Inc. insider transaction summary: On 08/20/2025 the company issued a $500,000 convertible promissory note to Alset Inc. that may be converted into common stock at $0.86 per share. The stated conversion would equate to 581,395 shares.
Reporting person and ownership: The filing is by Heng Fai Ambrose Chan and Alset Inc.; Mr. Chan is identified as a director and a greater-than-10% owner. The filing discloses Mr. Chan's total beneficial ownership of 6,730,059 shares, detailed by holdings across Heng Fai Holdings Limited, direct holdings, Alset Inc., Alset International Limited and Global Biomedical Pte. Ltd.
DSS, Inc. Schedule 13D/A shows that Heng Fai Ambrose Chan and affiliated entities control a large majority of the company’s common stock. Together they beneficially own 6,730,059 shares, representing 69.6% of the 9,092,518 shares outstanding as of August 21, 2025. Alset Inc. alone holds 4,542,606 shares (47.0%). On August 20, 2025, DSS issued a $500,000 convertible promissory note to Alset Inc. that may be converted into common stock at $0.86 per share. The filing lists the ownership breakdown across Heng Fai Holdings Limited, Alset entities and Global Biomedical, and cites a joint filing agreement as an exhibit.
FAQ
What is the current stock price of Dss (DSS)?
What is the market cap of Dss (DSS)?
